Feb 15 |
Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc
|
Feb 7 |
Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)
|
Feb 7 |
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024
|
Feb 7 |
Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib
|
Jan 29 |
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
|
Jan 22 |
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
|
Jan 18 |
Verastem gets FDA fast track status for lung cancer drug combo
|
Jan 18 |
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
|
Jan 11 |
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
Dec 18 |
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
|